JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes
September 06 2017 - 7:00AM
Business Wire
vTv Therapeutics and JDRF enter into a $6
million industry partnership to explore the effect of
liver-selective glucokinase activator TTP399 as an
insulin-adjunctive therapy in type 1 diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that JDRF,
the leading global organization funding type 1 diabetes (T1D)
research, will provide funding to support a Phase 2 Proof of
Concept study to explore the effect of vTv Therapeutics’
liver-selective glucokinase (GK) activator TTP399 as an oral drug
for the treatment of T1D. The study is designed to evaluate whether
TTP399 is well tolerated when administered as an add-on to insulin
therapy for people with T1D and can significantly improve daily
glucose profiles and HbA1c. JDRF has committed $3 million to the
study, and vTv will contribute an equal amount.
“At JDRF, we are committed to funding promising research with
the potential to cure, prevent and effectively treat type 1
diabetes,” said Esther Latres, director of research. “As we work
toward a cure, it’s crucial that we’re also championing progress
that will improve health outcomes and quality of life for people
living with T1D. TTP399’s novel mechanism of action, combined with
its oral administration, make it an ideal candidate for JDRF’s
Glucose Control Research Program. We are excited to collaborate
with the vTv Therapeutics team to bring this new treatment to those
living with the disease.”
“We are thrilled to partner with JDRF to explore TTP399 as a new
potential therapy for people with this life-threatening disease,”
said Carmen Valcarce, Ph.D., executive vice president, chief
scientific officer, vTv Therapeutics. “Based on the data we have
gathered thus far in our Phase 2 studies in type 2 diabetes, we are
optimistic that treatment with TTP399 will be well tolerated and
potentially offer an improved and simplified therapy for people
with type 1 diabetes.”
TTP399 is an orally available GK activator that is designed to
target GK activation only in the liver for superior glucose
control. In the liver, GK is a key regulator of glucose metabolism,
and its activation has been shown to increase glucose utilization,
which in turn lowers blood glucose. In a six-month Phase 2b
clinical trial of TTP399 in patients with type 2 diabetes, TTP399
demonstrated a statistically significant reduction in HbA1c levels
in all TTP399 dose groups compared with placebo. TTP399 was also
found to be well-tolerated without increased incidences of
hypoglycemia and hyperlipidemia compared to placebo.
About Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease in which a
person’s pancreas stops producing insulin, a hormone that enables
people to get energy from food. It occurs when the body’s immune
system attacks and destroys the insulin-producing cells in the
pancreas, called beta cells. While its causes are not yet entirely
understood, scientists believe that both genetic factors and
environmental triggers are involved. Its onset has nothing to do
with diet or lifestyle. There is nothing you can do to prevent T1D,
and—at present—nothing you can do to get rid of it.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness. Last year, vTv announced positive
topline results from a placebo and active-comparator-controlled
Phase 2b clinical study of TTP399, a liver-selective glucokinase
activator under development for the treatment of type 2
diabetes.
The Company’s drug candidates were discovered with its
high-throughput drug discovery platform, TTP Translational
Technology®, which translates the functional modulation of human
proteins into safe and effective medicines. For further company
information, visit www.vtvtherapeutics.com.
About JDRF
JDRF is the leading global organization funding type 1 diabetes
(T1D) research. Our mission is to accelerate life-changing
breakthroughs to cure, prevent and treat T1D and its complications.
To accomplish this, JDRF has invested more than $2 billion in
research funding since our inception. We are an organization built
on a grassroots model of people connecting in their local
communities, collaborating regionally for efficiency and broader
fundraising impact, and uniting on a national stage to pool
resources, passion, and energy. We collaborate with academic
institutions, policymakers, and corporate and industry partners to
develop and deliver a pipeline of innovative therapies to people
living with T1D. Our staff and volunteers throughout the United
States and our six international affiliates are dedicated to
advocacy, community engagement and our vision of a world without
T1D. For more information, please visit jdrf.org or follow us on
Twitter: @JDRF.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906005720/en/
vTv Therapeutics Inc.Investors:Michael Gibralter,
646-378-2938IR@vtvtherapeutics.comorMedia:Pure
Communications Inc.Katie Engleman,
910-509-3977Katie@purecommunications.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024